NRx Pharmaceuticals
(NASDAQ) NRXP
NRx Pharmaceuticals Financials at a Glance
Market Cap
$175.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$2.29M
Net Income (TTM)
-$24.54M
EPS (TTM)
-$1.28
P/E Ratio
-3.28
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$4.17
Volume
764,368.021
Open
$4.15
Price
$4.17
Volume
764,368.021
Open
$4.15
Previous Close
$4.19
Daily Range
$4.04 - $4.26
52-Week Range
$1.62 - $5.06
Estimated Earnings Date
Aug 17, 2026
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$4.17
Volume
764,368.021
Open
$4.15
Previous Close
$4.19
Daily Range
$4.04 - $4.26
52-Week Range
$1.62 - $5.06
Estimated Earnings Date
Aug 17, 2026
NRXP News
My Top 3 Biotech Stocks for May 2026
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout NRx Pharmaceuticals
Industry
Pharmaceuticals
Sector
Health CareCEO
Jonathan C. Javitt, MD
Website
www.nrxpharma.comHeadquarters
Wilmington, DE 19801, US
NRXP Financials
Key Financial Metrics (TTM)
Gross Margin
37.11%
Operating Margin
-749.67%
Net Income Margin
-1070.26%
Return on Equity
107.73%
Return on Capital
N/A
Return on Assets
-206.17%
Earnings Yield
-30.49%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$175.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
41.94M
Volume
764.37K
Avg. Volume
1.31M
Financials (TTM)
Gross Profit
$851.00K
Operating Income
-$17.19M
EBITDA
-$23.33M
Operating Cash Flow
-$14.93M
Capital Expenditure
$0.00
Free Cash Flow
-$14.93M
Cash & ST Invst.
$6.71M
Total Debt
$934.00K
NRx Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.07M
N/A
Gross Profit
$272.00K
N/A
Gross Margin
25.47%
N/A
Market Cap
$175.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$6.06M
N/A
Employees
29
N/A
Net Income
-$1.43M
+74.1%
EBITDA
-$1.03M
+81.3%
Quarterly Fundamentals
Total Cash
$6.71M
+21.0%
Total Debt
$934.00K
-88.9%
Accounts Receivable
$181.00K
N/A
Inventory
$0.00
N/A
Long Term Debt
$543.00K
N/A
Short Term Debt
$391.00K
-95.3%
Return on Assets
-2.06%
N/A
Return on Invested Capital
1.30%
N/A
Free Cash Flow
-$4.30M
-23.4%
Operating Cash Flow
-$4.30M
-23.4%